Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].

J Vignau1, L Karila, O Costisella

  • 1Service d'Addictologie, CHRU de Lille.

L'Encephale
|September 6, 2005
PubMed
Summary

Hepatitis C virus (HCV) infection is linked to depression, and Interferon alpha (IFNalpha) treatment can cause psychiatric side effects. Understanding these mechanisms is crucial for managing patient care and expanding treatment access.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Efficacy of psychedelics in psychiatry, a systematic review of the literature].

L'Encephale·2021
Same author

Obsessive-compulsive disorder and pelvic organ prolapse.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[Addictions].

Revue des maladies respiratoires·2019
Same author

Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.

Alimentary pharmacology & therapeutics·2018
Same author

[The Script Concordance Test: A multimodal teaching tool].

La Revue de medecine interne·2018
Same author

Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients.

Diagnostic microbiology and infectious disease·2018

Area of Science:

  • Neuroscience
  • Immunology
  • Hepatology

Context:

  • Hepatitis C virus (HCV) infection affects 1.2% of the French population, often leading to chronic infection and associated psychiatric symptoms like depression.
  • HCV infection rates are elevated in specific subgroups, including intravenous drug users, individuals with alcohol abuse, and psychiatric inpatients, though the reasons remain unclear.
  • Interferon alpha (IFNalpha), a cytokine used therapeutically for viral infections and cancers, is known to induce psychobehavioral symptoms, including depression.

Purpose:

  • To explore the pathophysiological mechanisms linking Hepatitis C virus (HCV) infection and depression.
  • To investigate the role of Interferon alpha (IFNalpha) in inducing psychiatric side effects, particularly depression, during Hepatitis C treatment.
  • To highlight the necessity of understanding these mechanisms for improved patient management and expanded treatment access.

Related Experiment Videos

Summary:

  • IFNalpha treatment for Hepatitis C is associated with depression, with reported frequencies ranging from 0% to 37%, potentially due to immune system involvement.
  • Psychobehavioral symptoms under IFNalpha treatment, including cognitive impairments and EEG changes, suggest a mild subcortical dementia, possibly mediated by cytokines acting as second messengers.
  • IFNalpha influences the serotonergic system by decreasing tryptophan availability and altering serotonin metabolism, and selective serotonin reuptake inhibitors (SSRIs) can prevent or treat IFNalpha-induced depression.

Impact:

  • A deeper understanding of IFNalpha's psychiatric side effects is essential for including patient groups currently excluded from treatment protocols.
  • Improved management of these psychiatric side effects will enable clinicians to better support at-risk patients, such as those with a history of depression or substance abuse.
  • Addressing the psychiatric aspects of IFNalpha therapy is critical, as a significant proportion of potential candidates for interferon treatment belong to these vulnerable populations.